Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 85/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A

2(40.0%)

Phase 1

2(40.0%)

Early Phase 1

1(20.0%)

5Total

N/A(2)

Phase 1(2)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT02849470Phase 1Withdrawn

AGA Biocellular Stem/Stromal Hair Regenerative Study

Role: collaborator

NCT04238143Not ApplicableRecruiting

Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis

Role: collaborator

NCT03909750Phase 1Suspended

Use of Autologous Stem/Stromal Cells In Chronic Lung Disorders: Obstructive (COPD) & Restrictive (RLD)

Role: collaborator

NCT04326036Early Phase 1Unknown

Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection

Role: collaborator

NCT03090672Not ApplicableUnknown

Cellular & Biocellular Regenerative Therapy in Musculoskeletal Pain, Dysfunction,Degenerative or Inflammatory Disease

Role: lead

All 5 trials loaded